<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Ophthalmology Product Guide &#187; InSite Vision</title>
	<atom:link href="http://www.ophthalmologyproductguide.com/blog/tag/insite-vision/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ophthalmologyproductguide.com/blog</link>
	<description>A comprehensive guide to ophthalmology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:36:57 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>FDA Recommends Approval for Ophthalmic Product Enabled By InSite&#8217;s DuraSite&#174; Technology</title>
		<link>http://www.ophthalmologyproductguide.com/blog/2009/01/02/fda-recommends-approval-for-ophthalmic-product-enabled-by-insites-durasite-technology/</link>
		<comments>http://www.ophthalmologyproductguide.com/blog/2009/01/02/fda-recommends-approval-for-ophthalmic-product-enabled-by-insites-durasite-technology/#comments</comments>
		<pubDate>Fri, 02 Jan 2009 12:14:32 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Conjunctiva]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[bacterial conjunctivitis]]></category>
		<category><![CDATA[Bausch & Lomb]]></category>
		<category><![CDATA[DuraSite®]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[InSite Vision]]></category>

		<guid isPermaLink="false">http://www.ophthalmologyproductguide.com/blog/2009/01/02/fda-recommends-approval-for-ophthalmic-product-enabled-by-insites-durasite%c2%ae-technology/</guid>
		<description><![CDATA[InSite Vision Incorporated has announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to recommend approval of Bausch &#38; Lomb&#8217;s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis, a product that utilizes InSite Vision&#8217;s DuraSite® patented drug delivery system. DuraSite is a synthetic polymer [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.ophthalmologyproductguide.com/blog/wp-content/uploads/2009/01/insite-vision.png" align="left" height="71" hspace="5" vspace="5" width="196" /><a href="http://www.insitevision.com/">InSite Vision</a> Incorporated has announced that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to recommend approval of Bausch &amp; Lomb&#8217;s besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis, a product that utilizes InSite Vision&#8217;s DuraSite® patented drug delivery system. DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules in an aqueous matrix, allowing for targeted and sustained administration. DuraSite enables a less frequent dosing schedule, increased patient compliance, and increased efficacy.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ophthalmologyproductguide.com/blog/2009/01/02/fda-recommends-approval-for-ophthalmic-product-enabled-by-insites-durasite-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
